Unlocking the Potential of FDA Expedited Approval and Voucher Programs: An Avance Clinical Partnership Approach

Breakthrough Therapy Designation: Maximizing Innovation Recognition

Purpose and Features: This designation provides intensive FDA guidance and rolling review for drugs demonstrating substantial improvement over available therapies based on preliminary clinical evidence.

Avance Clinical’s Value: We help sponsors identify the optimal timing for Breakthrough Therapy designation requests, often during Phase II development when preliminary efficacy signals are strongest. Our regulatory affairs specialists coordinate the enhanced FDA interactions that come with this designation, ensuring sponsors maximize the strategic value of frequent regulatory feedback.

Strategic Planning: Through our clinical development consulting services, we help sponsors design trials that generate the compelling preliminary clinical evidence required for Breakthrough Therapy designation. Our biostatistics team ensures data packages demonstrate the substantial improvement threshold FDA requires.

Accelerated Approval: Managing Risk and Opportunity

Purpose and Features: Accelerated Approval permits earlier market access based on surrogate endpoints reasonably likely to predict clinical benefit, coupled with mandatory post-marketing confirmatory trials.

Avance Clinical’s Risk Management: We provide comprehensive post-marketing study planning and execution services, recognizing that Accelerated Approval success depends on confirmatory trial design and effective execution. Our clinical operations team ensure post-marketing commitments are fulfilled efficiently, protecting market authorization.

Endpoint Strategy: Our regulatory consulting team works closely with sponsors to identify and validate surrogate endpoints that meet FDA expectations while supporting commercial objectives. We coordinate FDA interactions to gain endpoint concurrence before pivotal trial initiation.

Priority Review: Optimizing Regulatory Timelines

Purpose and Features: Priority Review shortens the standard review period from 10 to 6 months for therapies offering significant safety or efficacy improvements for serious conditions. Programs qualifying for Fast Track, Breakthrough Therapy, and Accelerated Approval can also be eligible for Priority Review.

Avance Clinical’s Submission Excellence: Our regulatory writing and submission teams ensure Priority Review applications meet the highest quality standards, recognizing that compressed timelines leave no room for major deficiencies or information requests. We coordinate mock FDA review sessions to identify potential issues before submission.

FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program: A Game Changer

Revolutionary Timeline Compression: Launched in June 2025, the CNPV program represents the most aggressive timeline compression in FDA history, potentially reducing review periods from 10 months to just 1-2 months for qualifying programs.

Eligibility and Alignment: The CNPV program targets drugs and biologics addressing public health crises, innovative cures, unmet medical needs, domestic manufacturing priorities, or affordability improvements. Avance Clinical’s regulatory strategy team conducts detailed alignment assessments to determine CNPV eligibility and optimize application positioning.

Operational Excellence Under Pressure: The CNPV program demands unprecedented operational agility. Requirements include pre-submission of chemistry, manufacturing, and controls (CMC) data and proposed labeling 60 days prior to NDA/BLA submission, followed by intensive “tumor board style” multi-disciplinary review sessions with FDA.

Avance Clinical’s CNPV Mastery: We provide comprehensive CNPV program management, including:

• Accelerated Documentation Preparation: Our regulatory writing teams work under compressed timelines to deliver submission-ready CMC and labeling materials that meet FDA expectations for completeness and quality.
• Real-Time Communication Management: We coordinate intensive, sometimes daily, interactions with FDA reviewers through dedicated communication specialists who ensure rapid response while maintaining sponsor team focus on strategic priorities.
• Mock Review Board Preparation: Our regulatory consultants conduct simulated FDA review sessions, preparing Sponsor teams for the unique multi-disciplinary evaluation format.
• Project Management Excellence: We provide structured project management support that enables sponsors to navigate the intensive regulatory cadence while maintaining internal operational efficiency.